Medtronic

Strategic intent

Medtronic is a global healthcare technology company that develops, manufactures, and distributes medical devices and therapies across cardiovascular, medical surgical, neuroscience, and diabetes portfolios.

Key market signals

• 2024-10: Received FDA approval for the Affera Mapping and Ablation System.
• 2024-08: Received FDA approval for the Simplera continuous glucose monitor (CGM).
• 2024-06: CFO Karen Parkhill departed the company to join HP, with Gary Corona stepping in as interim CFO.
• 2024-05: Reported FY24 full-year revenue of $32.36 billion, demonstrating mid-single-digit organic growth.

Financial health

• Reported FY24 worldwide revenue of $32.36 billion, an increase of 3.6% as reported (Source: https://news.medtronic.com/2024-05-23-Medtronic-reports-fourth-quarter-and-fiscal-year-2024-financial-results)

Impact & compliance

Legal & risks

Over the past 24 months, Medtronic has faced ongoing regulatory scrutiny typical of large medical device manufacturers, including Class I FDA recalls for devices such as the McGrath MAC video laryngoscope and certain neurovascular catheters, alongside standard industry product liability litigation a

Forensic audit — 1 findings

• ⚠ In July 2024, the US FDA designated the recall of Medtronic's McGrath MAC video laryngoscopes as Class I, the most serio...

Classifications

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.